Ionis hits seven-year high after partner GSK reveals promising hepatitis B trial results
07/01/2026 16:21
** Drugmaker Ionis Pharmaceuticals' IONS.O shares rise 4.8% to $85.41, hitting a nearly seven-year high ** Co's partner GSK GSK.L announces positive results for hepatitis B therapy in late-stage trial ** The drug, licensed from IONS, blocks replication of the hepatitis B virus and reduces production of proteins linked to the infection ** The drug could generate over 2 billion pounds ($2.70 billion) in annual sales, says GSK ** GSK plans to file for regulatory approval in first quarter of 2026 ** IONS stock price more than doubled in 2025 (Reporting by Utkarsh Tushar Hathi) ((utkarshtushar.hathi@thomsonreuters.com))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors